Biotech - Spark Newswire

2 minute read

FDA
News

Y-mAbs Highlights Frontline Data For DANYELZA In High-Risk Neuroblastoma To Be Presented At American Society of Clinical Oncology Jun. 4

Today, 2:48 AM

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based

YMAB

3 minute read

Allogene Therapeutics Highlights Phase 1 Data On ALLO-501 And ALLO-501A In Relapsed/Refractory Non-Hodgkin Lymphoma At 2021 ASCO Meeting

By Benzinga Newsdesk

Today, 2:48 AM

ASCO Posters Detail Results from ALLO-501 ALPHA and ALLO-501A ALPHA2 Trials in Non-Hodgkin Lymphoma and Safety and PK/PD Data of ALLO-647 with Flu/Cy Across the ALPHA, ALPHA2 and UNIVERSAL Studies Results from

ALLO

2 minute read

FDA
News

Athenex Highlights Data For 2 Poster Presentations At American Society Of Clinical Oncology

By Benzinga Newsdesk

Today, 2:48 AM

Data from oral docetaxel phase I pharmacokinetic study shows oral administration can achieve exposure comparable to IV docetaxel Post-hoc subgroup efficacy analysis based on updated tumor subtypes in the oral

ATNX

4 minute read

FDA
News

AbbVie Offers Extended Long-Term Data From Phase 3 Study Of IMBRUVICA vs Chlorambucil For Patents With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma At American Society Of Clinical Oncology Jun. 4

By Benzinga Newsdesk

Today, 2:48 AM

With up to seven years of data, progression-free and overall survival benefits continue to be observed with first-line single-agent IMBRUVICA treatment in CLL patients including selected patients with or without

ABBV

2 minute read

TRACON Pharmaceuticals Presents Data From Phase 1 Study Of Uliledlimab (TJ004309) And Tecentriq (Atezolizumab) At ASCO Meeting

By Benzinga Newsdesk

Today, 2:48 AM

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, today presented updated data from the

TCON

2 minute read

FDA
News

G1 Therapeutics Presents Phase 1 Data At ASCO Describing ‘Favorable Safety Profile and Evidence Of Antitumor Activity Of Rintodestrant Combined With Palbociclib In Patients With ER+/HER2- Advanced Breast Cancer’

By Benzinga Newsdesk

Today, 2:48 AM

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from its Phase 1 study of its oral selective estrogen receptor degrader (SERD), rintodestrant,

GTHX

2 minute read

FDA
News

Natera Announces New Prospera Data At ATC 2021 Virtual Connect Conference

By Benzinga Newsdesk

Today, 2:48 AM

Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on its latest scientific innovations in cfDNA testing at the American

NTRA

2 minute read

FDA
News

DarioHealth Releases Study Co Says Demonstrates Impact Of Personalized Digital Interventions To Improve Self-Management Of Diabetes

By Benzinga Newsdesk

Today, 2:48 AM

DarioHealth Corp. (NASDAQ:DRIO), a leader in the global digital therapeutics (DTx) market, announced today it will be presenting results of a new study at the 14th International Conference on Advanced Technologies

DRIO

2 minute read

Bristol Myers Touts Opdivo Win in Esophageal Cancer, But Yervoy-Opdivo Combo Comes with Caution

By Vandana Singh

Today, 2:48 AM

Bristol Myers Squibb & Co (NYSE: BMY) announced results from the Phase 3 CheckMate-648 trial, which had two Opdivo-based treatment combinations…

BMY

1 minute read

FDA
News

Travere Therapeutics Highlights Abstract Presentations At European Renal Association – European Dialysis and Transplant Association Congress Jun. 5-7

By Benzinga Newsdesk

Today, 2:48 AM

Travere Therapeutics (NASDAQ:TVTX) today announced presentations including nonclinical data examining the renal protective effects of sparsentan, a high affinity antagonist of both endothelin type A (ETA) and angiotensin

TVTX